PVLA - Latest News

Palvella Therapeutics, Inc. (PVLA), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $1.98B. Beta to the broader market is -0.17.

The article list below shows the most recent PVLA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent PVLA Headlines

Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger

seekingalpha.com - Sep 29, 2026

Palvella Therapeutics, Inc. advances QTORIN rapamycin for microcystic lymphatic malformations, completing NDA submission with strong Phase 3 data and

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

globenewswire.com - Sep 28, 2026

NDA submission completed following positive Phase 3 SELVA results; potential U. S.

Palvella Therapeutics Appoints James R. Treat, M.D.

globenewswire.com - Sep 9, 2026

Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

globenewswire.com - Sep 2, 2026

WAYNE, Pa. , Sept.

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

globenewswire.com - Aug 31, 2026

QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pe

How News Affects PVLA Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PVLA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked PVLA news questions

What is the latest PVLA news headline?

The most recent PVLA headline (Sep 29, 2026) is "Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the PVLA news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What PVLA news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual PVLA options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.